Taking a step forward in CAR T-cell therapy for acute myeloid leukaemia and myelodysplastic syndrome
Mené sur 25 patients atteints d'une leucémie myéloïde aiguë réfractaire ou récidivante, d'un syndrome myélodysplasique ou d'un myélome multiple (durée médiane de suivi : 118 jours), cet essai multicentrique de phase I évalue la dose maximale tolérée de CYAD-01, une immunothérapie à base de lymphocytes CAR-T autologues ciblant les ligands du récepteur NKG2D
Chimeric antigen receptor (CAR) T-cell therapies have transformed the treatment landscape of lymphoid malignancies. Six CAR T-cell products have been approved by the US Food and Drug Administration since 2017. 1 , 2 , 3 , 4 , 5 A single dose of autologous CD19-directed CAR T-cells showed objective response rates of 64–95% for patients with relapsed or refractory B-cell malignancies, with a subset of responding patients having durable remission. 1 , 2 , 3 Similarly, B-cell maturation antigen (BCMA) targeting CAR T-cells have yielded promising efficacy in relapsed and refractory multiple myeloma. 4 , 5 Unfortunately, equivalent success using CAR T-cells has yet to be replicated in myeloid malignancies, with no CAR T-cell products approved for this indication due to a paucity of efficacy or excessive toxicities.
The Lancet Haematology , commentaire, 2022